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AntitubercularAbstract New series of N-[2-{2-(substitutedphenyl)-4-oxo-5-(substitutedbenzylidene)-1,3-thiazoli-
dine}-iminoethyl]-2-amino-5-nitrothiazole, 5(a–m) have been synthesized from 2-amino-5-nitro-
thiazole as a starting material by conventional as well as microwave methods. All the synthesized
compounds 4(a–m) were screened for their antibacterial and antifungal activities against some
selected bacteria and fungi and antitubercular activity screened againstMycobacterium tuberculosis.
The structure of all the synthesized compounds were conﬁrmed by chemical and spectral analyses
such as IR, 1H NMR, 13C NMR and FAB-Mass.
ª 2011 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
4-Thiazolidine derivatives are an important class of heterocy-
clic compounds known for their potential pharmaceutical
applications. Recently, this framework containing compounds
were effective against antimicrobial (Young et al., 2004),
antischistosomal activity (Taha and Soliman, 2007),
antifungal (Asati et al., 2005), antiinﬂammatory (Jain et al.,
2006), antimalarial (Kristina et al., 2009), herbicidal(Sanemitsu et al., 2006), antiviral (Eiichi et al., 2007),
antidiabetic (Murugan et al., 2009), and antioxidant (Shih
and Ke, 2004) activities. Thiazole derivatives are heterocyclic
compounds containing nitrogen and sulfur atoms in their
structure and are proved to be clinically useful agents against
different kinds of disease. Thiazole derivatives have been
employed in the preparation of different important drugs
required for treatment of antimicrobial (Gouda et al., 2010),
antibacterial (Bharti et al., 2010; Khalil et al., 2009),
antifungal (Bharti et al., 2010; Joshi and Srivastava, 2001),
antiinﬂammatory (Giri et al., 2009), and antitubercular
(Shiradkar et al., 2007), some of the thiazole derivatives are
used as antiprotozoal (Ricardo et al., 2003) drugs. All
above biological activities of thiazole and thiazolidine
derivatives aroused our attention and promoted to
synthesis a new series of N-[2-{2-(substitutedphenyl)-4-oxo-5-
(substitutedbenzylidene)-1,3-thiazolidine}-iminoethyl]-2-amino-
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658 P. Samadhiya et al.5-nitrothiazole, 5(a–m) by conventional and microwave
methods. The structure of compounds 1, 2, 3(a–m), 4(a–m) and
5(a–m) were conﬁrmed by IR, 1H NMR, 13C NMR, FAB-
Mass and chemical analysis. All the ﬁnal synthesized
compounds 5(a–m) were screened for their antimicrobialTable 1 Data of yield and reaction time of all synthesized compou
Yield% Reaction time
Comp. Conv. MW Conv. (h) MW (min)
1st stirr. 2nd reﬂux
1 62 76 6.30 – 4.00
2 70 85 5.00 – 3.10
3a 60 78 3.00 2.15 3.35
3b 64 86 3.15 2.00 3.45
3c 67 83 3.10 2.00 3.35
3d 65 85 3.15 1.45 4.10
3e 67 84 2.30 2.15 3.15
3f 65 81 3.30 2.30 3.05
3g 63 80 3.35 2.00 2.40
3h 64 77 3.30 2.30 3.15
3i 62 78 3.30 1.40 3.30
3j 61 82 3.25 2.30 2.55
3k 62 81 3.30 2.30 3.45
3l 61 79 3.30 2.20 4.15
3m 62 81 3.30 2.00 3.25
4a 65 75 2.45 3.05 3.35
4b 65 79 2.30 3.15 3.35
4c 67 84 2.45 2.30 3.15
4d 66 82 2.30 2.30 3.10
4e 60 80 2.30 3.00 3.30
4f 63 83 2.15 3.15 3.05activity against some selected bacteria, fungi and
antituberculosis study against M. tuberculosis. (Scheme 1)
2. Materials and methods
2.1. Experimental
Melting points were taken in open glass capillaries and are
uncorrected. Progress of the reaction was monitored by silica
gel-G coated TLC plates in MeOH:CHCl3 system (1:9). The
spot was visualized by exposing dry plate in iodine vapours.
IR spectra were recorded in KBr disc on a Schimadzu 8201
PC, FTIR spectrophotometer (mmax in cm
1) and 1H and 13C
NMR spectra were measured on a Brucker DRX-300 spec-
trometer in CDCl3 at 300 and 75 MHz respectively using
TMS as an internal standard. All chemical shifts were reported
on d scales. The FAB-Mass spectra were recorded on a Jeol
SX-102 mass spectrometer. Elemental analyses were per-
formed on a Carlo Erba-1108 analyzer. Microwave irradiation
was carried out in an open glass vessel. Modiﬁed microwave
oven (800 W) was used for the synthesis of compounds.
A thermocouple was used to monitor the temperature inside
the vessel of the microwave. The analytical data of all the com-
pounds were highly satisfactory. For column chromatographic
puriﬁcation of the products, Merck silica Gel 60 (230–400
Mesh) was used. The reagent grade chemicals were
purchased from the commercial sources and further puriﬁed
before use.
2.2. General microwave method for synthesis of compound 1, 2,
3(a–m), 4(a–m) and 5(a–m)
A solid supported mixture of compounds (1:1 mol) was mixed
thoroughly in open glass vessel and subjected to the microwavends.
Yield% Reaction time
Comp. Conv. MW Conv. (h) MW (min)
1st stirr. 2nd reﬂux
4g 66 80 2.35 3.25 3.30
4h 64 76 2.45 3.15 3.35
4i 63 80 2.15 3.30 3.15
4j 61 84 2.30 3.30 3.05
4k 64 83 2.15 3.35 3.20
4l 63 77 2.15 3.30 3.20
4m 63 80 2.10 3.45 3.20
5a 66 79 2.30 3.15 3.40
5b 64 76 2.00 3.05 3.20
5c 62 82 2.05 2.45 3.20
5d 64 84 2.15 2.45 3.25
5e 62 83 2.10 3.10 3.30
5f 65 82 2.15 3.00 3.15
5g 64 78 2.30 3.15 3.45
5h 62 79 2.00 3.30 3.30
5i 64 81 2.10 3.25 3.15
5j 60 80 2.15 3.15 3.15
5k 66 82 2.00 3.30 3.20
5l 61 75 2.20 3.25 3.45
5m 62 76 2.30 3.45 3.20
– – – – – –
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4.15 min, then allowed to cool. The products were puriﬁed
over a column chromatography. The products were recrystal-
lized from ethanol at room temperature to yield compound
1,2, 3(a–m), 4(a–m) and 5(a–m). Results were given in Table 1.
2.3. Conventional method for synthesis of the compound 1
A mixture of 2-amino-5-nitrothiazole and 1-bromo-2-chloro-
ethane (1:1 mol) was dissolved in methanol at room tempera-
ture. The reaction mixture was continuously stirred on a
magnetic stirrer for about 6.30 h. The product was ﬁltered
and puriﬁed over a column chromatography using chloroform:
methanol (8:2 v/v). The puriﬁed product was recrystallized
from ethanol at room temperature to yield compound 1.
2.3.1. Synthesis of N-(2-chloroethyl)-2-amino-5-nitrothiazole
(1)
Yield: 62%, m.p. 162–166 C; Anal. Calcd for C5H6N3O2SCl:
C, 28.92, H, 2.91, N, 20.23%; found C, 28.90, H, 2.89, N,
20.13%; IR (cm1): 740 (CACl), 892 (CAS), 978 (CANO),
1382 (NACH2), 1555 (NO2), 1569 (C‚C), 2880, 3074 (CH),
3382 (NH); 1H NMR (d): 4.20 (t, 2H, J= 7.60 Hz, CH2ACl),
4.80 (t, 2H, J= 7.60 Hz, NACH2), 7.80 (br s, 1H, NH), 7.23
(s, 1H, C4H of thiazole);
13C NMR (d): 44.4 (CH2ACl), 56.5
(NACH2), 111.2 (C5 of thiazole), 137.5 (C4 of thiazole),
167.5 (C2 of thiazole), Mass (FAB): 208M
+, 172, 158, 144,
129, 117, 114, 99, 83.
2.4. Conventional method for synthesis of the compound 2
Amixture of compound 1 and hydrazine hydrate (1:1 mol) was
dissolved in methanol at room temperature. The reaction mix-
ture was continuously stirred on a magnetic stirrer for about
5.00 h. The product was ﬁltered and puriﬁed over a column
chromatography using chloroform: methanol (7:3 v/v). The
puriﬁed product was recrystallized from ethanol at room tem-
perature to yield compound 2.
2.4.1. Synthesis of N-{2-(hydrazino)-ethyl}-2-amino-5-
nitrothiazole (2)
Yield: 70%, m.p. 142–146 C; Anal. Calcd for C5H9N5O2S: C,
29.55, H, 4.46, N, 34.46%; found C, 29.50, H, 4.42, N,
34.41%; IR: 870 (CAN), 878 (CAS), 1338 (NACH2), 1528
(NO2), 3376 (NH), 3370 (NH), 3480 (NH2);
1H NMR (d):
4.27 (t, 2H, J= 7.60 Hz, CH2ANH), 4.92 (t, 2H,
J= 7.60 Hz, NACH2), 5.55 (s, 2H, NH2), 7.70 (s, 1H, NH),
7.96 (br s, 1H, NH), 7.25 (s, 1H, C4H of thiazole);
13C
NMR (d): 47.5 (CH2ANH), 57.4 (NACH2), 107.8 (C5 of thia-
zole), 138.8 (C4 of thiazole), 169.9 (C2 of thiazole); Mass
(FAB): 203M+, 187, 172.
2.5. General conventional method for synthesis of compound
3(a–m)
A mixture of compound 2 and substituted benzaldehydes
(1:1 mol) was dissolved in methanol at room temperature
and allowed to react. The reaction mixture was ﬁrst continu-
ously stirred on a magnetic stirrer for about 2.30–3.35 h then
kept on a steam bath for about 1.45–2.30 h. The products were
cooled and ﬁltered. The products were puriﬁed over a column
chromatography using chloroform: ethanol (8:2 v/v) andrecrystallized from ethanol at room temperature to yield com-
pound 3(a–m).
2.5.1. Synthesis of N-{2-(benzylidenimino)-ethyl}-2-amino-5-
nitrothiazole (3a)
Yield: 60%, m.p. 151–154 C; Anal. Calcd for C12H13N5O2S:
C, 49.47, H, 4.49, N, 24.03%; found C, 49.40, H, 4.42, N,
24.00%; IR: 1553 (N‚CH), 3378 (NH); 1H NMR (d): 4.25
(t, 2H, J= 7.45 Hz, CH2ANH), 4.78 (t, 2H, J= 7.45 Hz,
NACH2), 7.60 (s, 1H, NH), 7.76 (br s, 1H, NH), 7.89 (s, 1H,
N‚CH), 7.21 (s, 1H, C4H of thiazole), 6.38–7.36 (m, 5H,
ArAH); 13C NMR (d): 46.5 (CH2AN), 54.9 (NACH2), 112.4
(C5 of thiazole),140.9 (C4 of thiazole), 141.6 (N‚CH), 167.9
(C2 of thiazole), 124.7, 127.8, 127.8, 129.6, 130.2, 137.9 (6C,
Ar); Mass (FAB): 291M+, 214, 187.
2.5.2. Synthesis of N-{2-(4-chlorobenzylidenimino)-ethyl}-2-
amino-5-nitrothiazole (3b)
Yield: 64%, m.p. 162–166 C; Anal. Calcd for
C12H12N5O2SCl: C, 44.24, H, 3.71, N, 21.49%; found C,
44.22, H, 3.69, N, 21.45%; IR: 740 (CACl), 1562 (N‚CH),
3372 (NH); 1H NMR (d): 4.55 (t, 2H, J= 7.40 Hz,
CH2ANH), 4.90 (t, 2H, J= 7.40 Hz, NACH2), 7.36 (s, 1H,
C4H of thiazole), 7.55 (s, 1H, NH), 7.82 (br s, 1H, NH),
8.02 (s, 1H, N‚CH), 6.45–7.65 (m, 4H, ArAH); 13C NMR
(d): 49.6 (CH2ANH), 58.5 (NACH2), 116.8 (C5 of thiazole),
143.5 (C4 of thiazole), 152.7 (N‚CH), 174.5 (C2 of thiazole),
126.8, 128.6, 128.9, 130.8, 135.7, 138.6 (6C, Ar); Mass (FAB):
326M+, 290, 214, 201, 187, 180.
2.5.3. Synthesis of N-{2-(3-chlorobenzylidenimino)-ethyl}-2-
amino-5-nitrothiazole (3c)
Yield: 67%, m.p. 167–170 C; Anal. Calcd for
C12H12N5O2SCl: C, 44.24, H, 3.71, N, 21.49%; found C,
44.20, H, 3.70, N, 21.40%; IR: 747 (CACl), 1560 (N‚CH),
3384 (NH); 1H NMR (d): 4.58 (t, 2H, J= 7.45 Hz,
CH2ANH), 4.95 (t, 2H, J= 7.45 Hz, NACH2), 7.40 (s, 1H,
C4H of thiazole), 7.60 (s, 1H, NH), 7.76 (br s, 1H, NH),
8.09 (s, 1H, N‚CH), 6.40–7.69 (m, 4H, ArAH); 13C NMR
(d): 45.5 (CH2ANH), 48.3 (NACH2), 114.3 (C5 of thiazole),
143.4 (C4 of thiazole), 153.8 (N‚CH), 173.8 (C2 of thiazole),
126.8, 128.7, 129.8, 130.5, 135.5, 139.2A (6C, Ar); Mass
(FAB): 326M+.
2.5.4. Synthesis of N-{2-(2-chlorobenzylidenimino)-ethyl}-2-
amino-5-nitrothiazole (3d)
Yield: 65%, m.p. 162–165 C; Anal. Calcd for C12H12N5O2SCl:
C, 44.24, H, 3.71, N, 21.49%; found C, 44.18, H, 3.68, N,
21.42%; IR: 741 (CACl), 1560 (N‚CH), 3372 (NH); 1H
NMR (d): 4.56 (t, 2H, J= 7.50 Hz, CH2ANH), 4.98 (t, 2H,
J= 7.50 Hz, NACH2), 7.36 (s, 1H, C4H of thiazole), 7.53 (s,
1H, NH), 7.80 (br s, 1H, NH), 8.12 (s, 1H, N‚CH), 6.35–7.71
(m, 4H,ArAH); 13CNMR(d): 48.4 (CH2ANH), 58.6 (NACH2),
112.4 (C5 of thiazole), 142.7 (C4 of thiazole), 155.9 (N‚CH),
173.8 (C2 of thiazole), 127.6, 128.9, 130.8, 131.7, 135.8, 139.8
(6C, Ar); Mass (FAB): 326M+.
2.5.5. Synthesis of N-{2-(4-bromobenzylidenimino)-ethyl}-2-
amino-5-nitrothiazole (3e)
Yield: 67%, m.p. 172–175 C; Anal. Calcd for
C12H12N5O2SBr: C, 38.93, H, 3.26, N, 18.91%; found C,
38.90, H, 3.22, N, 18.89%; IR: 632 (CABr), 1609 (N‚CH),
660 P. Samadhiya et al.3372 (NH); 1H NMR (d): 4.50 (t, 2H, J= 7.50 Hz,
CH2ANH), 5.10 (t, 2H, J= 7.50 Hz, NACH2), 7.27 (s, 1H,
C4H of thiazole), 7.64 (s, 1H, NH), 7.90 (br s, 1H, NH),
8.02 (s, 1H, N‚CH), 6.53–7.90 (m, 4H, ArAH); 13C NMR
(d): 48.7 (CH2ANH), 56.2 (NACH2), 112.7 (C5 of thiazole),
142.8 (C4 of thiazole), 152.5 (N‚CH), 167.5 (C2 of thiazole),
125.9, 127.2, 128.6, 129.4, 135.7, 137.9 (6C, Ar); Mass (FAB):
370M+, 290, 214.
2.5.6. Synthesis of N-{2-(3-bromobenzylidenimino)-ethyl}-2-
amino-5-nitrothiazole (3f)
Yield: 65%, m.p. 177–180 C; Anal. Calcd for
C12H12N5O2SBr: C, 38.93, H, 3.26, N, 18.91%; found C,
38.90, H, 3.20, N, 18.89%; IR: 640 (CABr), 1570 (N‚CH),
3370 (NH); 1H NMR (d): 4.54 (t, 2H, J= 7.45 Hz, CH2 –
NH), 4.95 (t, 2H, J= 7.45 Hz, NACH2), 7.28 (s, 1H, C4H of
thiazole), 7.61 (s, 1H, NH), 7.88 (br s, 1H, NH), 8.06 (s, 1H,
N‚CH), 6.54–7.92 (m, 4H, ArAH); 13C NMR (d): 48.4
(CH2AN), 57.5 (NACH2), 113.8 (C5 of thiazole), 145.2 (C4 of
thiazole),155.4 (N‚CH), 167.4 (C2 of thiazole), 126.3, 127.8,
128.7, 130.8, 135.9, 138.5 (6C, Ar); Mass (FAB): 370M+.
2.5.7. Synthesis of N-{2-(2-bromobenzylidenimino)-ethyl}-2-
amino-5-nitrothiazole (3g)
Yield: 63%,m.p. 173–176 C; Anal. Calcd for C12H12N5O2SBr:
C, 38.93, H, 3.26, N, 18.91%; found C, 38.88, H, 3.20, N,
18.83%; IR: 647 (CABr), 1570 (N‚CH), 3370 (NH); 1H
NMR (d): 4.58 (t, 2H, J= 7.40 Hz, CH2ANH), 5.10 (t, 2H,
J= 7.40 Hz, NACH2), 7.28 (s, 1H, C4H of thiazole), 7.54 (s,
1H, NH), 7.85 (br s, 1H, NH), 8.11 (s, 1H, N‚CH), 6.62–7.92
(m, 4H,ArAH); 13CNMR(d): 49.6 (CH2ANH), 58.4 (NACH2),
113.3 (C5 of thiazole), 142.5 (C4 of thiazole), 156.2 (N‚CH),
169.6 (C2 of thiazole), 126.6, 127.8, 129.8, 130.6, 136.7, 138.8
(6C, Ar); Mass (FAB): 370M+.
2.5.8. Synthesis of N-{2-(4-nitrobenzylidenimino)-ethyl}-2-
amino-5-nitrothiazole (3h)
Yield: 64%, m.p. 169–172 C; Anal. Calcd for C12H12N6O4S:
C, 42.85, H, 3.59, N, 24.98%; found C, 42.80, H, 3.52, N,
24.93%; IR: 848 (CAN), 1549 (N‚O), 1576 (N‚CH), 3370
(NH); 1H NMR (d): 4.60 (t, 2H, J= 7.35 Hz, CH2ANH),
5.05 (t, 2H, J= 7.35 Hz, NACH2), 7.36 (s, 1H, C4H of thia-
zole), 7.45 (s, 1H, NH), 7.99 (br s, 1H, NH), 8.17 (s, 1H,
N‚CH), 7.04–8.05 (m, 4H, ArAH); 13C NMR (d): 49.7
(CH2AN), 59.3 (NACH2), 113.9 (C5 of thiazole), 143.7 (C4
of thiazole), 154.8 (N‚CH), 170.8 (C2 of thiazole), 127.6,
128.8, 129.7, 131.9, 136.7, 143.9 (6C, Ar); Mass (FAB):
336M+, 306, 290, 214.
2.5.9. Synthesis of N-{2-(3-nitrobenzylidenimino)-ethyl}-2-
amino-5-nitrothiazole (3i)
Yield: 62%, m.p. 166–169 C; Anal. Calcd for C12H12N6O4S:
C, 42.85, H, 3.59, N, 24.98%; found C, 42.82, H, 3.55, N,
24.94%; IR: 842 (CAN), 1536 (N‚O), 1572 (N‚CH), 3370
(NH); 1H NMR (d): 4.50 (t, 2H, J= 7.50 Hz, CH2ANH),
4.94 (t, 2H, J= 7.50 Hz, NACH2), 7.50 (s, 1H, NH), 7.90
(br s, 1H, NH), 7.45 (s, 1H, C4H of thiazole), 8.13 (s, 1H,
N‚CH), 7.10–8.20 (m, 4H, ArAH); 13C NMR (d): 47.9
(CH2ANH), 57.6 (NACH2), 114.6 (C5 of thiazole), 143.8 (C4
of thiazole), 154.7 (N‚CH), 170.8 (C2 of thiazole), 125.7,
129.8, 130.9, 131.6, 137.8, 144.6 (6C, Ar); Mass (FAB):
336M+.2.5.10. Synthesis of N-{2-(2-nitrobenzylidenimino)-ethyl}-2-
amino-5-nitrothiazole (3j)
Yield: 61%, m.p. 163–165 C; Anal. Calcd for C12H12N6O4S:
C, 42.85, H, 3.59, N, 24.98%; found C, 42.83, H, 3.55, N,
24.90%; IR: 845 (CAN), 1542 (N‚O), 1570 (N‚CH), 3344
(NH); 1H NMR (d): 4.42 (t, 2H, J= 7.50 Hz, CH2ANH),
4.69 (t, 2H, J= 7.50 Hz, NACH2), 7.45 (s, 1H, NH), 7.95 (br
s, 1H, NH), 7.34 (s, 1H, C4H of thiazole), 8.09 (s, 1H, N‚CH),
6.95–8.10 (m, 4H, ArAH); 13C NMR (d): 49.4 (CH2ANH), 59.8
(NACH2), 116.9 (C5 of thiazole), 144.8 (C4 of thiazole), 156.6
(N‚CH), 171.8 (C2 of thiazole), 126.4, 129.7, 131.3, 131.6,
138.5, 145.8 (6C, Ar); Mass (FAB): 336M+.
2.5.11. Synthesis of N-{2-(4-methoxybenzylidenimino)-ethyl}-
2-amino-5-nitrothiazole (3k)
Yield: 62%, m.p. 139–142 C; Anal. Calcd for C13H15N5O3S:
C, 48.58, H, 4.70, N, 21.79%; found C, 48.555, H, 4.62, N,
21.72%; IR: 1569 (N‚CH), 2948 (OCH3), 3368 (NH);
1H
NMR (d): 4.49 (t, 2H, J= 7.45 Hz, CH2ANH), 4.66 (s, 3H,
OCH3), 4.98 (t, 2H, J= 7.45 Hz, NACH2), 7.32 (s, 1H, C4H
of thiazole), 7.46 (s, 1H, NH), 7.73 (br s, 1H, NH), 7.91 (s,
1H, N‚CH), 6.66–7.59 (m, 4H, ArAH); 13C NMR (d): 48.7
(CH2ANH), 52.5 (OCH3), 57.7 (NACH2), 154.8 (N‚CH),
171.4 (C2 of thiazole), 114.8 (C5 of thiazole), 138.7 (C4 of thi-
azole), 113.7, 117.6, 123.8, 127.5, 136.9, 161.8 (6C, Ar); Mass
(FAB): 321M+, 306, 278, 214.
2.5.12. Synthesis of N-{2-(4-methylbenzylidenimino)-ethyl}-2-
amino-5-nitrothiazole (3l)
Yield: 61%, m.p. 135–138 C; Anal. Calcd for C13H15N5O2S:
C, 51.13, H, 4.95, N, 22.93%; found C, 51.10, H, 4.90, N,
22.91%; IR: 1549 (N‚CH), 2927 (CH3), 3360 (NH);
1H
NMR (d): 2.61 (s, 3H, CH3), 4.38 (t, 2H, J= 7.40 Hz,
CH2ANH), 4.92 (t, 2H, J= 7.40 Hz, NACH2), 7.16 (s, 1H,
C4H of thiazole), 7.32 (s, 1H, NH), 7.60 (br s, 1H, NH),
7.86 (s, 1H, N‚CH), 6.65–7.45 (m, 4H, ArAH); 13C NMR
(d): 26.6 (CH3), 47.4 (CH2ANH), 56.5 (NACH2), 111.4 (C5
of thiazole), 137.9 (C4 of thiazole), 152.8 (N‚CH), 171.5
(C2 of thiazole), 124.4, 127.7, 128.6, 129.6, 134.5, 137.6 (6C,
Ar); Mass (FAB): 305M+, 279, 214.
2.5.13. Synthesis of N-{2-(4-hydroxybenzylidenimino)-ethyl}-2-
amino-5-nitrothiazole (3m)
Yield: 62%, m.p. 131–134 C; Anal. Calcd for C12H13N5O3S:
C, 46.89, H, 4.26, N, 22.78%; found C, 46.85, H, 4.22, N,
22.73%; IR: 1559 (N‚CH), 3388 (NH), 3477 (OH); 1H
NMR (d): 4.53 (t, 2H, J= 7.35 Hz, CH2ANH), 4.29 (s, 1H,
OH), 5.09 (t, 2H, J= 7.35 Hz, NACH2), 7.30 (s, 1H, C4H
of thiazole), 7.57 (s, 1H, NH), 7.78 (br s, 1H, NH), 7.90 (s,
1H, N‚CH), 6.50–7.49 (m, 4H, ArAH); 13C NMR (d): 49.5
(CH2ANH), 59.7 (NACH2), 112.8 (C5 of thiazole), 140.6 (C4
of thiazole), 153.4 (N‚CH), 170.6 (C2 of thiazole), 111.7,
116.4, 123.8, 128.9, 137.5, 154.8 (6C, Ar); Mass (FAB)1:
307M+, 290, 216, 181.
2.6. General conventional methods for synthesis of compound
4(a–m)
A mixture of compound 3(a–m) and thioglycolic acid (1:1 mol)
dissolved in methanol was allow to react in the presence of a
catalytic amount of ZnCl2. The reaction mixture was
ﬁrst continuously stirred on a magnetic stirrer for about
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80–90 C. The products were cooled and ﬁltered at room
temperature. The ﬁltered products were puriﬁed over column
chromatography using chloroform: ethanol (7:3 v/v) and recrys-
tallized from ethanol at room temperature to yield compound
4(a–m).
2.6.1. Synthesis of N-2-[-{-(2-phenyl-4-oxo-1-3-thiazolidine}-
imino]-ethyl-2-amino-5-nitrothiazole (4a)
Yield: 65%, m.p. 161–164 C; Anal. Calcd for C14H15N5O3S2:
C, 46.01, H, 4.13, N, 19.16%; found C, 45.96, H, 4.10, N,
19.10%; IR: 678 (CASAC), 748 (CACl), 1329 (CAN), 1738
(CO cyclic), 2912 (SACH2);
1H NMR 3.10 (s, 2H, SACH2),
4.96 (d, 1H, NACH), 7.26 (s, 1H, C4H of thiazole), 6.45–
7.45 (m, 4H, ArAH); 13C NMR (d): 35.5 (CH2AS), 56.2
(NACH), 111.8 (C5 of thiazole), 137.8 (C4 of thiazole), 168.7
(CO cyclic), 170.6 (C2 of thiazole), 124.7, 126.7, 127.5, 128.8,
131.9, 137.7 (6C, Ar); Mass (FAB): 365M+, 337, 260, 187,
178. 150.
2.6.2. Synthesis of N-2-[-{2-(4-chlorophenyl)-4-oxo-1-3-
thiazolidine-imino}-ethyl-2-amino-5-nitrothiazole (4b)
Yield: 65%, m.p. 178–181 C; Anal. Calcd for
C14H14N5O3S2Cl: C, 42.05, H, 3.52, N, 17.51%; found C,
42.00, H, 3.49, N, 17.47%; IR: 689 (CASAC), 738 (CACl),
1345 (CAN), 1749 (CO cyclic), 2946 (SACH2);
1H NMR:
3.30 (s, 2H, SACH2), 4.98 (d, 1H, NACH), 7.31 (s, 1H, C4H
of thiazole), 6.64–7.78 (m, 4H, ArAHAH); 13C NMR (d):
34.4 (CH2AS), 58.2 (NACH), 116.7 (C5 of thiazole), 140.4
(C4 of thiazole), 177.9 (CO cyclic), 171.8 (C2 of thiazole),
124.7, 126.8, 127.7, 128.5, 129.8, 138.5 (6C, Ar); Mass
(FAB): 400M+, 372, 365, 185, 178.
2.6.3. Synthesis of N-2-[-{2-(3-chlorophenyl)-4-oxo-1-3-
thiazolidine-imino}-ethyl-2-amino-5-nitrothiazole (4c)
Yield: 67%, m.p. 176–178 C; Anal. Calcd for
C14H14N5O3S2Cl: C, 42.05, H, 3.52, N, 17.51%; found C,
42.01, H, 3.46, N, 17.45%; IR: 672 (CASAC), 749 (CACl),
1338 (CAN), 1744 (CO cyclic), 2930 (SACH2);
1H NMR:
3.40 (s, 2H, SACH2), 4.90 (d, 1H, NACH), 7.40 (s, 1H, C4H
of thiazole), 6.72–7.74 (m, 4H, ArAH); 13C NMR (d): 39.5
(CH2AS), 53.4 (NACH), 109.7 (C5 of thiazole), 139.5 (C4 of
thiazole), 176.9 (CO cyclic), 171.6 (C2 of thiazole), 125.9,
127.8, 128.6, 128.6, 130.5, 136.9 (6C, Ar); Mass (FAB):
400M+.
2.6.4. Synthesis of N-2-[-{2-(2-chlorophenyl)-4-oxo-1-3-
thiazolidine}-imino]-ethyl-2-amino-5-nitrothiazole (4d)
Yield: 66%, m.p. 174–177 C; Anal. Calcd for
C14H14N5O3S2Cl: C, 42.05, H, 3.52, N, 17.51%; found C,
42.03, H, 3.49, N, 17.45%; IR: 678 (CASAC), 758 (CACl),
1339 (CAN), 1748 (CO cyclic), 2938 (SACH2);
1H NMR:
3.40 (s, 2H, SACH2), 4.93 (d, 1H, NACH), 7.36 (s, 1H, C4H
of thiazole), 6.67–7.76 (m, 4H, ArAH); 13C NMR (d): 39.6
(CH2AS), 60.7 (NACH), 112.5 (C5 of thiazole), 138.9 (C4 of
thiazole), 174.9 (CO cyclic), 172.5 (C2 of thiazole), 125.7,
127.6, 127.9, 128.4, 129.6, 137.9 (6C, Ar); Mass (FAB): 400M+.
2.6.5. Synthesis of N-2-[-{2-(4-bromophenyl)-4-oxo-1-3-
thiazolidine}-imino]-ethyl-2-amino-5-nitrothiazole (4e)
Yield: 60%, m.p. 187–190 C; Anal. Calcd for
C14H14N5O3S2Br: C, 37.84, H, 3.17, N, 15.76%; found C,37.80, H, 3.12, N, 15.76%; IR: 688 (CASAC), 758 (CABr),
1345 (CAN), 1748 (CO cyclic), 2946 (SACH2);
1H NMR:
3.42 (s, 2H, SACH2), 4.89 (d, 1H, NACH), 7.39 (s, 1H, C4H
of thiazole), 6.46–7.91 (m, 4H, ArAH); 13C NMR (d): 40.5
(CH2AS), 61.6 (NACH), 112.8 (C5 of thiazole), 139.8 (C4 of
thiazole), 173.9 (CO cyclic), 172.2 (C2 of thiazole), 125.8,
126.9, 127.6, 128.8, 129.8, 137.5 (6C, Ar); Mass (FAB):
444M+, 416, 364, 257, 229, 187, 177, 149.
2.6.6. Synthesis of N-2-[-{2-(3-bromophenyl)-4-oxo-1-3-
thiazolidine}-imino]-ethyl-2-amino-5-nitrothiazole (4f)
Yield: 63%, m.p. 185–187 C; Anal. Calcd for
C14H14N5O3S2Br: C, 37.84, H, 3.17, N, 15.76%; found C,
37.81, H, 3.10, N, 15.74%; IR: 670 (CASAC), 748 (CABr),
1339 (CAN), 1738 (CO cyclic), 2936 (SACH2);
1H NMR:
3.44 (s, 2H, SACH2), 4.85 (d, 1H, NACH), 7.30 (s, 1H, C4H
of thiazole), 6.61–7.98 (m, 4H, ArAH); 13C NMR (d): 38.4
(CH2AS), 54.3 (NACH), 110.2 (C5 of thiazole), 137.6 (C4 of
thiazole), 175.4 (CO cyclic), 171.2 (C2 of thiazole), 126.7,
127.8, 128.8, 129.6, 130.4, 137.3 (6C, Ar); Mass (FAB): 444.
2.6.7. Synthesis of N-2-[-{2-(2-bromophenyl)-4-oxo-1-3-
thiazolidine}-imino]-ethyl-2-amino-5-nitrothiazole (4g)
Yield: 66%, m.p. 180–183 C; Anal. Calcd for
C14H14N5O3S2Br: C, 37.84, H, 3.17, N, 15.76%; found C,
37.78, H, 3.11, N, 15.69%; IR: 675 (CASAC), 742 (CABr),
1332 (CAN), 1738 (CO cyclic), 2920 (SACH2);
1H NMR:
3.46 (s, 2H, SACH2), 4.88 (d, 1H, NACH), 7.32 (s, 1H, C4H
of thiazole), 6.85–7.96 (m, 4H, ArAH); 13C NMR (d): 34.6
(CH2AS), 51.6 (NACH), 113.4 (C5 of thiazole), 138.8 (C4 of
thiazole), 171.5 (CO cyclic), 167.6 (C2 of thiazole), 126.5,
127.6, 128.8, 129.4, 130.8, 137.3 (6C, Ar); Mass (FAB): 444M+.
2.6.8. Synthesis of N-2-[-{2-(4-nitrophenyl)-4-oxo-1-3-
thiazolidine}-imino]-ethyl-2-amino-5-nitrothiazole (4h)
Yield: 64%, m.p. 187–189 C; Anal. Calcd for C14H14N6O5S2:
C, 40.96, H, 3.43, N, 20.47%; found C, 40.93, H, 3.40, N,
20.40%; IR: 687 (CASAC), 1020 (NO), 1329 (CAN), 1548
(NO2), 1748 (CO cyclic), 2936 (SACH2);
1H NMR: 3.40 (s,
2H, SACH2), 4.85 (d, 1H, NACH), 7.32 (s, 1H, C4H of thia-
zole), 6.98–7.97 (m, 4H, ArAH); 13C NMR (d): 38.7 (CH2AS),
57.4 (NACH), 113.4 (C5 of thiazole), 138.4 (C4 of thiazole),
174.6 (CO cyclic), 169.2 (C2 of thiazole), 126.7, 127.7, 128.6,
129.8, 129.9, 136.6 (6C, Ar); Mass (FAB): 410M+, 380, 364,
336, 280, 223, 195, 149, 117.
2.6.9. Synthesis of N-2-[-{2-(3-nitrophenyl)-4-oxo-1-3-
thiazolidine}-imino]-ethyl-2-amino-5-nitrothiazole (4i)
Yield: 63%, m.p. 182–186 C; Anal. Calcd for C14H14N6O5S2:
C, 40.96, H, 3.43, N, 20.47%; found C, 40.90, H, 3.39, N,
20.41%; IR: 674 (CASAC), 745 (CACl), 1020 (NO), 1326
(CAN), 1547 (NO2), 1746 (CO cyclic), 2986 (SACH2);
1H
NMR: 3.37 (s, 2H, SACH2), 4.94 (d, 1H, NACH), 7.39 (s, 1H,
C4H of thiazole), 6.90–8.13 (m, 4H, ArAH);
13C NMR (d):
42.8 (CH2AS), 61.7 (NACH), 111.7 (C5 of thiazole), 139.6 (C4
of thiazole), 173.9 (CO cyclic), 172.1 (C2 of thiazole), 126.8,
127.8, 128.8, 129.9, 131.9, 135.7 (6C, Ar); Mass (FAB): 410M+.
2.6.10. Synthesis of N-2-[-{2-(2-nitrophenyl)-4-oxo-1-3-
thiazolidine}-imino]-ethyl-2-amino-5-nitrothiazole (4j)
Yield: 61%, m.p. 179–181 C; Anal. Calcd for C14H14N6O5S2:
C, 40.96, H, 3.43, N, 20.47%; found C, 40.92, H, 3.38, N,
662 P. Samadhiya et al.20.42%; IR: 670 (CASAC), 743 (CACl), 1012 (NO), 1325
(CAN), 1539 (NO2), 1736 (CO cyclic), 2988 (SACH2);
1H
NMR: 3.31 (s, 2H, SACH2), 4.97 (d, 1H, NACH), 7.39 (s,
1H, C4H of thiazole), 7.02–8.11 (m, 4H, ArAH);
13C NMR
(d): 45.8 (CH2AS), 60.6 (NACH), 114.4 (C5 of thiazole),
141.5 (C4 of thiazole), 172.2 (C2 of thiazole), 174.6 (CO cyclic),
126.3, 127.8, 128.7, 129.6, 130.5, 138.9 (6C, Ar); Mass (FAB):
410M+.
2.6.11. Synthesis of N-2-[-{2-(4-methoxyphenyl)-4-oxo-1-3-
thiazolidine}-imino]-ethyl-2-amino-5-nitrothiazole (4k)
Yield: 64%, m.p. 165–167 C; Anal. Calcd for C15H17N5O4S2:
C, 45.55, H, 4.33, N, 17.70%; found C, 45.52, H, 4.30, N,
17.65%; IR: 670 (CASAC), 1334 (CAN), 1742 (CO cyclic),
2935 (SACH2), 3024 (OCH3);
1H NMR: 3.25 (s, 2H, SACH2),
3.58 (s, 3H, OCH3), 4.89 (d, 1H, NACH), 7.29 (s, 1H, C4H of
thiazole), 6.66–7.69 (m, 4H, ArAH); 13C NMR (d): 41.6
(CH2AS), 57.9 (NACH), 53.8 (OCH3), 111.8 (C5 of thiazole),
138.8 (C4 of thiazole), 171.8 (CO cyclic), 172.6 (C2 of thiazole),
125.6, 127.8, 128.4, 129.6, 133.4, 139.4 (6C, Ar); Mass (FAB):
395M+, 380, 367, 364, 352, 336, 208, 193, 187, 180, 177.
2.6.12. Synthesis of N-2-[-{2-(4-methylphenyl)-4-oxo-1-3-
thiazolidine}-imino]-ethyl-2-amino-5-nitrothiazole (4l)
Yield: 63%, m.p. 163–165 C; Anal. Calcd for C15H17N5O3S2:
C, 47.47, H, 4.51, N, 18.45%; found C, 47.43, H, 4.47, N,
18.40%; IR: 670 (CASAC), 743 (CACl), 1327 (CAN), 1740
(CO cyclic), 2933 (SACH2), 2932 (CH3);
1H NMR: 2.77 (s,
3H, CH3), 3.29 (s, 2H, SACH2), 4.74 (d, 1H, NACH), 7.32
(s, 1H, C4H of thiazole), 6.49–7.74 (m, 4H, ArAH);
13C
NMR (d): 27.4 (CH3), 46.6 (CH2AS), 60.6 (NACH), 109.5
(C5 of thiazole), 137.8 (C4 of thiazole), 172.4 (CO cyclic),
167.2 (C2 of thiazole), 126.9, 127.7, 128.3, 132.7, 136.9 (6C,
Ar); Mass (FAB): 379M+, 353, 325, 261.
2.6.13. Synthesis of N-2-[-{2-(4-hydroxyphenyl)-4-oxo-1-3-
thiazolidine}-imino]-ethyl-2-amino-5-nitrothiazole (4m)
Yield: 63%, m.p. 160–162 C; Anal. Calcd for C14H15N5O4S2:
C, 44.08, H, 3.96, N, 18.36%; found C, 44.02, H, 3.93, N,
18.32%; IR: 679 (CASAC), 1336 (CAN), 1743 (CO cyclic),
2938 (SACH2), 3449 (OH);
1H NMR: 3.40 (s, 2H, SACH2),
4.46 (s, 1H, OH), 4.81 (d, 1H, NACH), 7.31 (s, 1H, C4H of thi-
azole), 6.54–7.45 (m, 4H, ArAH); 13C NMR (d): 50.7
(CH2AS), 61.5 (NACH), 111.7 (C5 of thiazole), 138.8 (C4 of
thiazole), 174.6 (CO cyclic), 168.6 (C2 of thiazole), 126.74,
127.6, 128.6, 129.8, 132.5, 137.5 (6C, Ar); Mass (FAB):
381M+, 364, 325, 194, 166.
2.7. General conventional method for synthesis of compound
5(a–m)
A mixture of compound 4(a–m) and substituted benzaldehydes
(1:1 mol) was dissolved in methanol in the presence of alkali
metal alkoxide (C2H5ONa) and allow to react. The reaction
mixture was ﬁrst continuously stirred on a magnetic stirrer
for about 2.00–2.30 h then kept on steam bath for about
2.45–3.45 h at 80–90 C. The products were cooled and ﬁltered
at room temperature. The ﬁltered products were puriﬁed over
column chromatography using chloroform: methanol (7:3 v/v)
and recrystallized from acetone at room temperature to yield
ﬁnal products compound 5(a–m).2.7.1. Synthesis of N-2-[-{2-phenyl-4-oxo-5-benylidene-1-3-
thiazolidine}-imino]-ethyl-2-amino-5-nitrothiazole (5a)
Yield: 66%, m.p. 161–163 C; Anal. Calcd for C21H19N5O3S2:
C, 55.61, H, 4.22, N, 15.44%; found C, 55.56, H, 4.20, N,
15.41%; IR: 1508 (C‚CH), 2978 (C‚CH); 1H NMR: 6.25
(s, 1H, C‚CH), 7.22 (s, 1H, C4H of thiazole), 6.42–7.42 (m,
10H, ArAH); 13C NMR (d): 110.6 (C5 of thiazole), 139.6 (C4
of thiazole), 143.6 (C‚CH), 146.8 (C‚CH), 170 (C2 of thia-
zole), 170.7 (CO cyclic), 124.5, 125.6, 125.9, 126.8, 126.9,
127.8, 127.9, 128.9, 128.9, 129.7, 137.8, 138.9 (12C, Ar); Mass
(FAB): 454M+, 426, 377, 349.
2.7.2. Synthesis of N-2-[-{2-(4-chlorophenyl)-4-oxo-5-
(4-chlorobenzylidene)-1-3-thiazolidine}-imino]-ethyl-2-amino-
5-nitrothiazole (5b)
Yield: 64%, m.p. 166–169 C; Anal. Calcd for
C21H17N5O3S2Cl2: C, 48.27, H, 3.27, N, 13.40%; found C,
48.20, H, 3.22, N, 13.36%; IR: 1520 (C‚CH), 2946 (C‚CH);
1H NMR: 6.47 (s, 1H, C‚CH), 7.32 (s, 1H, C4H of thiazole),
6.47–7.69 (m, 8H, ArAH); 13C NMR (d): 112.7 (C5 of thia-
zole), 141.5 (C4 of thiazole), 144.8 (C‚CH), 147.8 (C‚CH),
172.1 (C2 of thiazole), 175.7 (CO cyclic), 126.7, 127.6, 128.5,
128.9, 129.4, 129.8, 130.7, 131.6, 132.8, 133.8, 134.7, 138.9
(12C, Ar); Mass (FAB): 522M+, 494, 487, 411, 383, 307.
2.7.3. Synthesis of N-2-[-{-5-(3-chlorobenzylidene)-2-
(3-chlorophenyl)-4-oxo-1-3-thiazolidine}-imino]-ethyl-2-amino-
5-nitrothiazole (5c)
Yield: 62%, m.p. 164–166 C; Anal. Calcd for
C21H17N5O3S2Cl2: C, 48.27, H, 3.27, N, 13.40%; found C,
48.23, H, 3.21, N, 13.35%; IR: 1526 (C‚CH), 2952 (C‚CH);
1H NMR: 6.45 (s, 1H, C‚CH), 7.42 (s, 1H, C4H of thiazole),
6.58–7.60 (m, 8H, ArAH); 13C NMR (d): 111.6 (C5 of thia-
zole), 140.8 (C4 of thiazole), 143.5 (C‚CH), 146.8 (C‚CH),
171.5 (C2 of thiazole), 173.3 (CO cyclic), 126.2, 126.7, 127.4,
127.8, 128.3, 128.7, 129.5, 131.6, 132.8, 133.4, 134.2, 137.8
(12C, Ar); Mass (FAB): 522M+.
2.7.4. Synthesis of N-2-[-{2-(2-chlorophenyl)-4-oxo-5-
(2-chlorobenzylidene)-1-3-thiazolidine}-imino]-ethyl-2-amino-
5-nitrothiazole (5d)
Yield: 64%, m.p. 162–164 C; Anal. Calcd for
C21H17N5O3S2Cl2: C, 48.27, H, 3.27, N, 13.40%; found C,
48.25, H, 3.22, N, 13.33%; IR: 1525 (C‚CH), 2938 (C‚CH);
1H NMR: 6.48 (s, 1H, C‚CH), 7.46 (s, 1H, C4H of thiazole),
6.50–7.65 (m, 8H, ArAH); 13C NMR (d): 110.8 (C5 of thia-
zole), 139.9 (C4 of thiazole), 144.6 (C‚CH), 146.9 (C‚CH),
171.8 (C2 of thiazole), 173.4 (CO cyclic), 126.9, 126.9, 127.4,
127.8, 128.5, 129.8, 130.6, 132.8, 133.7, 134.4, 135.7, 138.8
(12C, Ar); Mass (FAB): 522M+.
2.7.5. Synthesis of N-2-[-{2-(4-bromophenyl)-4-oxo-5-
(4-bromobenzylidene)-1-3-thiazolidine}-imino]-ethyl-2-amino-
5-nitrothiazole (5e)
Yield: 62%, m.p. 168–172 C; Anal. Calcd for
C21H17N5O3S2Br2: C, 41.25, H, 2.80, N, 11.45%; found C,
41.19, H, 2.77, N, 11.43%; IR: 1517 (C‚CH), 2945 (C‚CH);
1H NMR: 6.40 (s, 1H, C‚CH), 7.42 (s, 1H, C4H of thiazole),
6.55–7.95 (m, 8H, ArAH); 13C NMR (d): 112.2 (C5 of thia-
zole), 140.8 (C4 of thiazole), 144.6 (C‚CH), 147.8 (C‚CH),
171.2 (C2 of thiazole), 173.9 (CO cyclic), 119.8, 123.4, 125.4,
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(12C, Ar); Mass (FAB): 611M+, 583, 531, 427, 424, 401,
396, 240, 214.
2.7.6. Synthesis of N-2-[-{2-(3-bromophenyl)-4-oxo-5-(3-
bromobenzylidene)-1-3-thiazolidine}-imino]-ethyl-2-amino-5-
nitrothiazole (5f)
Yield: 65%, m.p. 175–177 C; Anal. Calcd for
C21H17N5O3S2Br2: C, 41.25, H, 2.80, N, 11.45%; found C,
41. 20, H, 2.75, N, 11.40%; IR: 1521 (C‚CH), 2962 (C‚CH);
1H NMR: 6.24 (s, 1H, C‚CH), 6.58 (s, 1H, C4H of thiazole),
6.58–7.97 (m, 8H, ArAH); 13C NMR (d): 112.9 (C5 of thia-
zole), 139.9 (C4 of thiazole), 144.8 (C‚CH), 148.9 (C‚CH),
172.3 (C2 of thiazole), 174.7 (CO cyclic), 123.5, 124.7, 126.8,
127.5, 127.9, 128.5, 129.6, 129.8, 130.8, 132.8, 141.7, 142.6
(12C, Ar); Mass (FAB): 611M+.
2.7.7. Synthesis of N-2-[-{2-(2-bromophenyl)-4-oxo-5-(2-
bromobenzylidene)-1-3-thiazolidine}-imino]-ethyl-2-amino-5-
nitrothiazole (5g)
Yield: 64%, m.p. 176–178 C; Anal. Calcd for
C21H17N5O3S2Br2: C, 41.25, H, 2.80, N, 11.45%; found C,
41.22, H, 2.79, N, 11.42%; IR: 1526 (C‚CH), 2933 (C‚CH);
1H NMR: 6.52 (s, 1H, C‚CH), 7.32 (s, 1H, C4H of thiazole),
6.45–8.02 (m, 8H, ArAH); 13C NMR (d): 113.4 (C5 of thia-
zole), 141.4 (C4 of thiazole), 145.1 (C‚CH), 148.5 (C‚CH),
171.2 (C2 of thiazole), 176.7 (CO cyclic), 119.8, 120.8, 124.9,
125.4, 126.8, 127.6, 128.8, 128.9, 129.9, 130.7, 140.8, 142.6
(12C, Ar); Mass (FAB): 611M+.
2.7.8. Synthesis of N-2-[-{2-(4-nitrophenyl)-4-oxo-5-(4-
nitrobenzylidene)-1-3-thiazolidine}-imino]-ethyl-2-amino-5-
nitrothiazole (5h)
Yield: 62%, m.p. 171–174 C; Anal. Calcd for C21H17N7O7S2:
C, 46.40, H, 3.15, N, 18.03%; found C, 46.33, H, 3.11, N,
17.93%; IR: 1530 (C‚CH), 2991 (C‚CH); 1H NMR: 6.41
(s, 1H, C‚CH), 7.38 (s, 1H, C4H of thiazole), 6.85–8.22 (m,
8H, ArAH); 13C NMR (d): 112.2 (C5 of thiazole), 139.4 (C4
of thiazole), 143.6 (C‚CH), 146.5 (C‚CH), 174.7 (CO cyc-
lic), 170.2 (C2 of thiazole), 126.4, 127.6, 128.8, 128.6, 129.5,
138.8 (12C, Ar); Mass (FAB): 544M+, 540, 470, 444, 357, 327.
2.7.9. Synthesis of N-2-[-{2-(3-nitrophenyl)-4-oxo-5-(3-
nitrobenzylidene)-1-3-thiazolidine}-imino]-ethyl-2-amino-5-
nitrothiazole (5i)
Yield: 64%, m.p. 176–179 C; Anal. Calcd for C21H17N7O7S2:
C, 46.40, H, 3.15, N, 18.03%; found C, 46.37, H, 3.13, N,
17.98%; IR: 1522 (C‚CH), 2946 (C‚CH); 1H NMR: 6.48
(s, 1H, C‚CH), 7.44 (s, 1H, C4H of thiazole), 6.90–8.28 (m,
8H, ArAH); 13C NMR (d): 110.2 (C5 of thiazole), 138.4 (C4
of thiazole), 141.8 (C‚CH), 144.9 (C‚CH), 175.7 (CO cyc-
lic), 169.8 (C2 of thiazole), 118.7, 120.7, 124.9, 125.6, 126.7,
127.5, 128.6, 129.6, 130.4, 132.8, 146.8, 148.6 (12C, Ar); Mass
(FAB): 544M+.
2.7.10. Synthesis of N-2-[-{2-(2-nitrophenyl)-4-oxo-5-(2-
nitrobenzylidene)-1-3-thiazolidine}-imino]-ethyl-2-amino-5-
nitrothiazole (5j)
Yield: 60%, m.p. 177–180 C; Anal. Calcd for C21H17N7O7S2:
C, 46.40, H, 3.15, N, 18.03%; found C, 46.35, H, 3.08, N,
18.00%; IR: 1532 (C‚CH), 2948 (C‚CH); 1H NMR: 6.32
(s, 1H, C‚CH), 7.44 (s, 1H, C4H of thiazole), 6.82–8.20 (m,8H, ArAH); 13C NMR (d): 111.2 (C5 of thiazole), 140.4 (C4
of thiazole), 143.7 (C‚CH), 146.6 (C‚CH), 168.8 (C2 of thi-
azole), 175.7 (CO cyclic), 116.8, 121.6, 123.8, 125.7, 126.8,
127.6, 128.8, 129.6, 130.6 132.7, 145.6, 146.8 (12C, Ar); Mass
(FAB): 544M+.
2.7.11. Synthesis of N-2-[-{2-(4-methoxyphenyl)-4-oxo-5-(4-
methoxybenzylidene)-1-3-thiazolidine}-imino]-ethyl-2-amino-5-
nitrothiazole (5k)
Yield: 66%, m.p. 155–158 C; Anal. Calcd for C23H23N5O5S2:
C, 53.78, H, 4.51, N, 13.63%; found C, 53.72, H, 4.45, N,
13.56%; IR: 1518 (C‚CH), 2941 (C‚CH), 2978 (OCH3);
1H NMR: 3.63 (s, 3H, OCH3), 6.34 (s, 1H, C‚CH), 7.37 (s,
1H, C4H of thiazole), 6.45–7.77 (m, 8H, ArAH);
13C NMR
(d): 63.5 (OCH3), 108.7 (C5 of thiazole), 138.8 (C4 of thiazole),
144.8 (C‚CH), 148.5 (C‚CH), 170.5 (C2 of thiazole), 171.7
(CO cyclic), 114.7, 115.7, 120.8, 121.9, 124.6, 125.7, 127.8,
128.8, 128.9, 129.6, 155.6, 156.9 (12C, Ar); Mass (FAB):
514M+, 499, 486, 471, 443.
2.7.12. Synthesis of N-2-[-{2-(4-methylphenyl)-4-oxo-5-(4-
methylbenzylidene)-1-3-thiazolidine}-imino]-ethyl-2-amino-5-
nitrothiazole (5l)
Yield: 61%, m.p. 152–154 C; Anal. Calcd for C23H23N5O3S2:
C, 57.36, H, 4.81, N, 14.54%; found C, 57.30, H, 4.78, N,
14.50%; IR: 1512 (C‚CH), 2938 (C‚CH), 2970 (CH3);
1H
NMR: 2.80 (s, 3H, CH3), 6.35 (s, 1H, C‚CH), 7.38 (s, 1H,
C4H of thiazole), 6.30–7.90 (m, 8H, ArAH);
13C NMR (d):
26.9 (CH3), 107.2 (C5 of thiazole), 136.4 (C4 of thiazole),
141.1 (C‚CH), 146.9 (C‚CH), 170.3 (CO cyclic), 169.7 (C2
of thiazole), 123.7, 124.5, 125.6, 126.8, 126.8, 127.7, 127.9,
128.6, 129.7, 130.8, 138.6, 139.8 (12C, Ar); Mass (FAB):
482M+, 467, 454, 439, 363, 337.
2.7.13. Synthesis of N-2-[-{2-(4-hydroxyphenyl)-4-oxo-5-(4-
hydroxybenzylidene)-1-3-thiazolidine}-imino]-ethyl-2-amino-5-
nitrothiazole (5m)
Yield: 62%,m.p. 150–153 C;Anal. Calcd for C21H19N5O5S2: C,
51.94, H, 3.94, N, 14.42%; found C, 51.80, H, 3.82, N, 14.39%;
IR: 1501 (C‚CH), 2951 (C‚CH), 3478 (OH); 1HNMR: 4.94 (s,
1H, OH), 6.46 (s, 1H, C‚CH), 7.39 (s, 1H, C4H of thiazole),
6.48–7.58 (m, 8H, ArAH); 13C NMR (d): 113.5 (C5 of thiazole),
143.3 (C4 of thiazole), 146.1 (C‚CH), 148.5 (C‚CH), 171.2 (C2
of thiazole), 173.7 (CO cyclic), 120.9, 124.8, 125.7, 126.6, 127.8,
128.8, 128.9, 129.8, 131.3, 137.5, 138.6, 152.8 (12C, Ar); Mass
(FAB): 486M+, 458, 469, 384, 368, 308.3. Results and discussion
The reaction of 1-bromo-2-chloro-ethane with 2-amino-5-
nitrothiazole was carried out in methanol to afford a product
compound 1 The spectroscopic analyses of compound 1
showed absorption peaks for NACH and CACl at 1382 and
740 cm1 in the IR spectrum. In the IR spectrum conﬁrms
the formation of compound 1. This fact was also supported
by the disappearance of NH absorption of the 2-amino-
5-nitrothiazole. The compound 1 on the reaction with hydra-
zine hydrate with continuous stirring at room temperature
yielded compound 2. In the spectroscopic analyses of
compound 2 we found two absorption peaks in IR spectrum
for NH and NH2 at 3370 and 3480 cm
1 respectively while
664 P. Samadhiya et al.absorption of CACl has disappeared. This is clearly indicated
that compound 1 gives the substitution reaction with hydra-
zine hydrate. This fact was also supported by 1H and 13C
NMR spectra because two signals appeared in the 1H NMR
spectrum for NH and NH2 at d 7.70 and d 5.55 ppm respec-
tively. All the facts together were strong evidence for the syn-
thesis of compound 2. The compound 2 gave the condensation
reaction with substituted benzaldehydes resulting in the pro-
duction of Schiff bases N‚CH, compound 3(a–m) which
was conﬁrmed by IR, 1H NMR and 13C NMR spectra of com-
pound 3(a–m). In the IR spectra an absorption was found in
the range of 1549–1609 cm1 while a strong signal appeared
in the range of d 7.82–8.17 and d 141.6–156.6 ppm in the 1H
NMR and 13C NMR spectra for N‚CH of compound 3(a–
m) respectively. The facts have also supported by the disap-
pearance of the signal of NH2 in the
1H NMR spectra. The
compound 3(a–m) on reaction with equimolar amount of thio-
glycolic acid in the presence of ZnCl2 (act as a catalyst) in the
trace amount gives the cycloaddition reaction and produced a
ﬁve membered thiazolidinone ring, compound 4(a–m). The
compound 4(a–m) showed a characteristic absorption for the
cyclic carbonyl group in the range of 1738–1749 cm1 in the
IR spectra. The 1H NMR spectra aroused our attention and
clearly indicate the presence of the two active methylene pro-
tons in the thiazolidine ring in the range of d 3.10–3.46 ppm.
The 13C NMR spectra of compound 4(a–m) also supported
the fact that cyclic carbonyl group present and a signal
appeared in the range of d 168.7–177.9 ppm. All these facts
were also supported by the two evidences that are (a) disap-Table 3 Antitubercular activity of compounds 5(a–m).
Compound % Activity Compound % Activity C
25 ppm 50 ppm 25 ppm 50 ppm
5a 32 59 5e 50 78 5
5b 52 82 5f 60 79 5
5c 53 80 5g 59 76 5
5d 62 80 5h 62 82 5
Standards 100 100 Standards 100 100 S
Isoniazid and rifampicin were taken as standards, showed 100% activity
Table 2 Antibacterial activity of compounds 5(a–m).
Compound B. subtilis E. coli S. aureus
50 ppm 100 ppm 50 ppm 100 ppm 50 ppm 100 ppm
5a 17 21 17 22 15 23
5b 23 29 20 30 22 28
5c 24 34 22 32 24 30
5d 25 33 20 32 23 31
5e 22 30 22 31 25 33
5f 21 30 21 32 24 30
5g 20 28 20 29 20 27
5h 22 36 19 33 22 34
5i 20 37 20 32 22 33
5j 24 32 21 34 20 35
5k 18 25 19 24 18 24
5l 14 18 14 20 16 22
5m 12 27 23 27 17 28
Streptomycin 28 37 26 34 27 35pearance of N‚CH proton and (b) appearance of NACH pro-
ton in the range of d 4.74–4.98 ppm in the 1H NMR spectra of
compound 4(a–m). The compound 4(a–m) underwent the
Knoevenagel condensation reaction with substituted benzalde-
hydes in the presence of alkali metal alkoxide (C2H5ONa) to
afford the compound 5(a–m). In the 1H NMR spectra of the
compound 5(a–m), we found the disappearance of two methy-
lene protons of compound 5(a–m) and an appearance of a new
signal for C‚CH in the range of d 6.24–6.52 ppm in the 1H
NMR and two new signals for C‚CH and C‚CH appeared
in the range of d 141.1–146.1 and d 144.9–148.9 ppm in the 13C
NMR spectra of the compound 5(a–m). These all above facts
clearly conﬁrmed the synthesis of all ﬁnal products. All above
compounds 1, 2, 3(a–m), 4(a–m) and 5(a–m) were also synthe-
sized by microwave method. Characterization data were given
in Table 1. All these above facts clearly conﬁrmed the synthesis
of all ﬁnal products. Antimicrobial and antitubercular data (as
shown in Tables 2 and 3) revealed that all the synthesized com-
pound 5(a–m) have a structure activity relationship (SAR)
because activity of compounds varies with substitution. Nitro
group containing compounds (5h, 5i and 5j) showed higher
activity than chloro (5c, 5d), or bromo group containing com-
pounds (5e,5f). Chloro and bromo derivatives also have higher
activity than other rested compounds. On the basis of SAR, it
was concluded that the activity of compounds depends on the
electron withdrawing nature of the substituted groups. The
sequence of the activity is following
NO2 > Cl > Br > OCH3 < OH > CH3ompound % Activity Compound % Activity
25 ppm 50 ppm 25 ppm 50 ppm
i 57 83 5m 54 76
j 58 81 – – –
k 58 60 – – –
l 42 55 – – –
tandards 100 100 Standards 100 100
at 25 and 50 ppm concentrations.
Compound A. niger A. ﬂavus C. albicans
50 ppm 100 ppm 50 ppm 100 ppm 50 ppm 100 ppm
5a 09 15 17 20 17 20
5b 12 22 15 20 14 24
5c 16 30 12 24 14 30
5d 18 29 10 34 13 31
5e 15 28 12 28 15 31
5f 16 29 11 27 14 30
5g 14 28 10 31 10 28
5h 12 31 09 32 12 35
5i 12 29 10 31 12 33
5j 13 30 11 34 10 32
5k 11 19 10 24 11 23
5l 10 16 10 20 10 20
5m 14 24 13 25 12 27
Griseofulvin 22 32 20 35 24 36
Synthesis and biological evaluation of 4-thiazolidinone derivatives as antitubercular and antimicrobial agents 6654. Biological study
Series of newly synthesized compounds were highly active
against selected microorganisms. The minimal inhibition val-
ues were determined using the ﬁlter paper disc diffusion
method (Asati et al., 2005) and the concentrations have been
used in ppm. All the ﬁnal synthesized compounds 5(a–m)
have dissolved in methanol and screened in vitro for their
antibacterial activity against Bacillus subtilis, Escherichia coli
and Staphylococcus aureus and antifungal activity against
Aspergillus niger, Aspergillus ﬂavus and Candida albicans.
Standards for antibacterial and antifungal activity
streptomycin and griseofulvin were used respectively.
Standards also screened under the similar conditions for
comparison. The antitubercular activity screened against the
M. tuberculosis. For the antitubercular activity isoniazid and
rifampicin were used as standard and also screened under
the similar conditions.
4.1. Antibacterial activity
The above synthesized compounds were screened against some
selected bacteria and examined for the inhibition of growth of
the organism. The concentrations of the compounds were
given in ppm. The diameter of the inhibition zones in (mm)
were given in Table 2.
4.2. Antifungal activity
The above synthesized compounds were screened against
selected fungi and their minimal inhibition zones in (mm) were
presented in Table 2 and concentrations of the compounds
were given in ppm.
4.3. Antitubercular activity
The above synthesized compounds were screened against M.
tuberculosis (H37Rv strain) using L.J. medium (conventional)
method at 25 and 50 ppm concentrations. The results were
showing in Table 3. The standard antitubercular drugs isonia-
zid and rifampicin were taken as standards, showed 100%
activity at both the above concentrations.5. Conclusion
Compound 1, 2, 3(a–m), 4(a–m) and 5(a–m) were synthesized
by conventional and microwave methods, reaction time and
yields of the synthesized compound displayed that the micro-
wave method is more efﬁcient than the conventional method.
Compound 5(a–m) were screened for their antibacterial, anti-
fungal and antitubercular activity against selected microorgan-isms. The investigation of antimicrobial data revealed that the
compounds (5c), (5d), (5e), (5f), (5h), (5i) and (5j) displayed
highly active in the series, compounds (5b), ( 5g) and (5m)
showed moderate activity and rest compounds showed less
activity against all the strains compared with standard drugs.
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